Nurix, Inc. is a leader in discovering and developing a new class of drugs that work by modulating the protein regulation machinery of the cell.
The Nurix scientific team has established an innovative drug discovery platform based on recent advances in understanding of the ubiquitin proteasome system (UPS). The UPS is a regulatory network that controls protein homeostasis, the stabilization and degradation of cellular proteins. This process is vital to the healthy life of a cell and provides opportunities to discover new drugs in multiple disease areas.
Nurix’s Protein Regulation Platform enables the discovery of selective inhibitors or activators of the UPS, enabling the development of new class of drugs. In September 2015, Nurix entered into an exclusive collaboration with Celgene for the discovery and development of next-generation therapies targeting protein homeostasis in oncology, immunology and inflammation, including the rapidly evolving field of immuno-oncology.
Nurix was founded by internationally-recognized experts in the ubiquitin proteasome field and is funded by leading life science investors Third Rock Ventures and The Column Group. The company is headquartered in San Francisco, California.